Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Prior treatment

• Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment
• Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
• Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment
• Abnormal function of major organs (14 days before enrollment)

Other illness

• Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment

Other

• Abnormal results of blood routine examinations and liver and kidney and coagulation tests
• Women who are pregnant
• Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.

• ECOG PS 0-1
• Pathological tissue-confirmed unresectable locally advanced pancreatic cancer
• Pancreatic cancer patients who have not received systemic anti-tumor therapy
• Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards
• A life expectancy of \> 3 months
• Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl
• AST\<2.5 × ULN(Upper Limit of Normal), ALT\<2.5 × ULN,creatinine ≤1.5xULN, total bilirubin \< ≤1.5 X ULN.